SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: 3D image of a KRAS oncogene
Business
BridgeBio Spins Out Oncology Company with $200M in Financing
The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction between the RAS and PI3K pathways.
May 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's headquarters building in West London
Business
GSK Raises Full-Year Profit Guidance on Strong Q1 Vaccine Sales
GSK’s total sales increased 10% in the first quarter of 2024 compared to the same period last year, thanks in large part to demand for its shingles vaccine Shingrix and respiratory syncytial virus vaccine Arexvy.
May 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Skyline of Atlanta
Business
Atlanta’s Biotech Scene Prepares for New Heights
The Atlanta area is receiving more physical real estate options to foster its burgeoning biotech industry.
May 1, 2024
 · 
6 min read
 · 
Tyler Patchen
Pictured: Novartis' logo outside its building in S
Business
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.
April 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
Bristol Myers Squibb’s deal announced Monday will see the pharma pay $65 million upfront to Repertoire Immune Medicines, which will develop autoimmune disease vaccines using its Decode discovery platform.
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: X4 CEO Paula Ragan
FDA
FDA Approves First Targeted Treatment for WHIM Syndrome
After laying off staff in 2022 to extend its cash runway, X4 Pharmaceuticals got its drug for the ultra-rare immunodeficiency disease across the finish line on Monday.
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Update: AbbVie headquarters building in California
Business
AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq
Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.
April 26, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A child covering his ears over a neuron
Drug Development
As Autism Cases Rise, Biopharma Springs Into Action
Several companies—including Roche, Curemark and Yamo Pharmaceuticals—are running clinical trials of treatments that aim to offset the myriad challenges of autism.
April 25, 2024
 · 
6 min read
 · 
Tyler Patchen
Pictured: Sanofi US headquarters in Bridgewater, N
Business
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1
Sanofi is dropping its Sjögren’s syndrome candidate due to disappointing Phase II efficacy data, while AstraZeneca is stopping work on some early-stage assets amid a portfolio reprioritization.
April 25, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Photo illustration of hundred dollar bil
Drug Development
Endeavor Raises $132M in Oversubscribed Series C to Advance Lung Disease, ADC Candidates
While the San Diego-based biotech awaits a Phase IIa data readout for its lead lung disease candidate, Endeavor BioMedicines’ next-generation HER3-targeted antibody-drug conjugate will start a Phase I/II trial later this year.
April 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Novartis headquarters in Basel, Switzerl
Business
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales
The Swiss drugmaker raised its full-year guidance Tuesday projecting net sales to grow in the high-single to low double-digit range while reporting better-than-expected first-quarter results.
April 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bristol Myers Squibb office in California
Biotech Bay
BMS Taps Cellares in $380M CAR T Cell Therapy Manufacturing Agreement
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
April 22, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Injection pens meant for weight-loss medications
Business
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.
April 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Photo illustration of hundred dollar bill and graph
Biotech Bay
Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive
The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.
April 17, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Boehringer Ingelheim's office in California
Drug Development
Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030
The German biopharma company on Tuesday announced ambitious pipeline plans that include starting 10 new Phase II and III trials over the next 12 to 18 months.
April 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More